当前位置: X-MOL 学术Cancer Biol. Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT.
Cancer Biology & Therapy ( IF 4.4 ) Pub Date : 2020-08-13 , DOI: 10.1080/15384047.2020.1796195
Whitney F Handy 1 , Keith T Schmidt 2 , Douglas K Price 3 , William D Figg 2, 3
Affiliation  

The Chemohormonal Therapy vs Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) was a randomized phase III trial that evaluated the outcomes of men with metastatic prostate cancer who received castration with or without docetaxel. Patients from this trial were genotyped in a recent study to detect HSD3B1 variance and to determine 2-y freedom from castration-resistant prostate cancer as well as overall survival. The results of this study identified HSD3B1 as a possible biomarker that can be used to predict response to therapy in patients with metastatic disease.



中文翻译:

检查HSD3B1作为可能的生物标记物,以检测可能在ADT上进展的前列腺癌患者。

前列腺癌广泛性疾病的化学激素治疗与雄激素消融随机试验(CHAARTED)是一项随机III期临床试验,评估了接受或不接受多西他赛去势的转移性前列腺癌男性的结局。来自该试验的患者在最近的一项研究中进行了基因分型,以检测HSD3B1变异并确定2年无去势抵抗性前列腺癌以及总生存期。这项研究的结果确定了HSD3B1是可能的生物标志物,可用于预测转移性疾病患者对治疗的反应。

更新日期:2020-09-06
down
wechat
bug